Feb 18, 2026Partial Epigenetic Reprogramming for Vision Loss: Life Biosciences ER-100 TrialLife Biosciences received FDA clearance to begin the first human trial of partial epigenetic reprogramming using OSK Yamanaka factors delivered via AAV for glaucoma and NAION. Trial is in early stages; no human efficacy data exists yet.
Feb 18, 2026Gene Therapy for Telomere Biology Disorders: EXG-34217 Trial Results at Cincinnati Children'sEXG-34217, a gene therapy delivering functional TERT, showed telomere elongation and hematopoietic recovery in two patients with dyskeratosis congenita — a rare inherited disease, not general aging. Results published in NEJM Evidence.
Feb 9, 2026Gene Therapy for Aging: Telomerase Activation, AAV Delivery, Current Trials, and RisksGene therapy to extend healthspan is moving from animal studies to human trials. Telomerase activation via AAV delivery extended lifespan in mice. Human applications are in early development. The risks — including oncogenic potential — are significant and must be understood clearly.
Feb 8, 2026Epigenetic Reprogramming: Yamanaka Factors, Partial OSK Reprogramming, and the Clinical HorizonPartial epigenetic reprogramming using OSK (Oct4, Sox2, Klf4) Yamanaka factors has reversed multiple aging hallmarks in animal models without inducing cancer. Human translation is in early clinical development. This article explains the biology, current trials, and realistic timeline.